Cargando…

Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

In this review article we discuss the role of the memory T cells in multiple myeloma (MM) and how they may influence immune responses in patients that received immunomodulating drugs and check point therapy.

Detalles Bibliográficos
Autores principales:	Sponaas, Anne Marit, Waage, Anders, Vandsemb, Esten N., Misund, Kristine, Børset, Magne, Sundan, Anders, Slørdahl, Tobias Schmidt, Standal, Therese
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928324/ https://www.ncbi.nlm.nih.gov/pubmed/33679794 http://dx.doi.org/10.3389/fimmu.2021.636375

Ejemplares similares

The serine protease matriptase inhibits migration and proliferation in multiple myeloma cells
por: Steiro, Ida, et al.
Publicado: (2022)

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients
por: Sponaas, Anne-Marit, et al.
Publicado: (2018)

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade
por: Yang, Rui, et al.
Publicado: (2020)

Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
por: Våtsveen, Thea Kristin, et al.
Publicado: (2016)

The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells
por: Slørdahl, Tobias S., et al.
Publicado: (2016)

Targeting phosphoglycerate dehydrogenase in multiple myeloma
por: Elsaadi, Samah, et al.
Publicado: (2021)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Monitoring multiple myeloma by quantification of recurrent mutations in serum
por: Rustad, Even Holth, et al.
Publicado: (2017)

Identification of the source of elevated hepatocyte growth factor levels in multiple myeloma patients
por: Rampa, Christoph, et al.
Publicado: (2014)

Phosphatases of regenerating liver are key regulators of metabolism in cancer cells – role of Serine/Glycine metabolism
por: Abdollahi, Pegah, et al.
Publicado: (2022)

Highly expressed genes in multiple myeloma cells – what can they tell us about the disease?
por: Børset, Magne, et al.
Publicado: (2022)

Intracellular IL-32 regulates mitochondrial metabolism, proliferation, and differentiation of malignant plasma cells
por: Aass, Kristin Roseth, et al.
Publicado: (2021)

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
por: Suzuki, Kazuhito, et al.
Publicado: (2023)

Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance
por: Hjort, Magnus A., et al.
Publicado: (2017)

Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021)

IMiDs for myeloma induced renal impairment
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration
por: Vandsemb, Esten N., et al.
Publicado: (2016)

Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer
por: Tøndell, Anders, et al.
Publicado: (2019)

Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration
por: Hjort, Magnus Aassved, et al.
Publicado: (2018)

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide
por: Bartlett, J B, et al.
Publicado: (2005)

Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide
por: Furihata, Hirotake, et al.
Publicado: (2020)

Caspase‐8 regulates the expression of pro‐ and anti‐inflammatory cytokines in human bone marrow‐derived mesenchymal stromal cells
por: Moen, Siv H., et al.
Publicado: (2016)

c-Met signaling promotes IL-6-induced myeloma cell proliferation
por: Hov, Håkon, et al.
Publicado: (2009)

The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma
por: Sponaas, Anne M, et al.
Publicado: (2015)

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
por: Kopp, Katherine O., et al.
Publicado: (2023)

Inhibition of Cytosolic Phospholipase A2α Induces Apoptosis in Multiple Myeloma Cells
por: Mahammad, Nur, et al.
Publicado: (2021)

Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
por: Baranowska, Katarzyna, et al.
Publicado: (2016)

Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
por: Misund, Kristine, et al.
Publicado: (2022)

An IMiD-induced SALL4 degron system for selective degradation of target proteins
por: Yamanaka, Satoshi, et al.
Publicado: (2020)

309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations
por: Davis, Lorraine, et al.
Publicado: (2022)

Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma
por: Aass, Kristin Roseth, et al.
Publicado: (2022)

High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
por: Brenne, Anne-Tove, et al.
Publicado: (2009)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
por: Bouguenina, Habib, et al.
Publicado: (2023)

Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival
por: Roseth Aass, Kristin, et al.
Publicado: (2022)

The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
por: Heider, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_03b7q9gmmndjof0pl1kaiu1p9a